Completed PHASE4 INTERVENTIONAL 1-arm NCT03431714

Efficacy and Safety of ASAQ and PD for the Treatment of Uncomplicated Falciparum Malaria in Mainland Tanzania (GF-TES-2017)

Efficacy and Safety of Artesunate-amodiaquine and Dihydroartemisinin-piperaquine for the Treatment of Uncomplicated Falciparum Malaria in Mainland Tanzania

Sponsor: Muhimbili University of Health and Allied Sciences

Conditions Uncomplicated Falciparum Malaria

Interventions Artesunate amodiaquine

Updated 5 times since 2018 Last updated: Feb 12, 2018 Started: Jul 14, 2017 Primary completion: Dec 8, 2017 Completion: Dec 8, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03431714, this PHASE4 trial focuses on Uncomplicated Falciparum Malaria and remains completed. Sponsored by Muhimbili University of Health and Allied Sciences, it has been updated 5 times since 2017, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Mar 2018 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jul 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Muhimbili University of Health and Allied Sciences
National Institute for Medical Research, Tanzania
World Health Organization

Data source: National Institute for Medical Research, Tanzania

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tanga, Tanzania